CheckMate914
Por um escritor misterioso
Descrição
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
From neoadjuvant to second-line therapeutic options for RCC patients
CheckMate 914 Archives
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis - Mori - International Journal of Urology - Wiley Online Library
EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse
Advances in Adjuvant Therapy for Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Pembrolizumab Shows Promise
Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
.png)
ASCO热评丨盛锡楠教授：肾癌领域治疗进展-肿瘤瞭望
BMS joins Roche on the adjuvant kidney cancer flop list
A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)
A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)
Immunotherapy combo fails to extend disease-free survival in high-risk kidney cancer
Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, KEYNOTE-991
de
por adulto (o preço varia de acordo com o tamanho do grupo)
